Market News AIOpen the app

Dermata Therapeutics stock is going up on Thursday after good news from a study.

TrialRead the original at Benzinga
Good for DRMA

Dermata reported improvements across several skin measures in a 31-person, open-label study. The small study and self-reported results limit the proof, but support its newly launched treatment.

DRMA · Dermata Therapeutics Inc.

AI read · Good for DRMA

The AI's read

These findings give Dermata early support for its skin treatment. Participants reported noticing changes, and no treatment-related problems were reported. The study was small and open-label, so it cannot show how well the product works for a wider group or whether shoppers will keep buying it. The product is available online, but the story gives no sales figures.

Get alerts for DRMA

Follow Dermata Therapeutics Inc. (DRMA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DRMA
Free on the App Store and Google Play, or on the web.